Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging (SHAH)

University Hospital Center (CHU) Dijon Bourgogne

Status: Completed

Conditions: Pituitary Gland Failure; Hepatic Steatosis

Treatments: Biological: Blood samples; Other: NMR; Other: fibroscan

Study type: Interventional

Funder types: Other

Identifiers

NCT02814240

PETIT NOVARTIS 2014

Details and patient eligibility

About

The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.

Enrollment: 21 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have provided consent
• Patients over 18 years
• Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary.

Exclusion criteria

• Persons without national health insurance
• Pacemaker (Contra-Indication for MRI)
• Alcohol consumption greater than 4 glasses a day
• Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden
• Presence of metallic implants (Contra-Indication for MRI)
• Claustrophobia
• Adult under guardianship
• Pregnant or breast-feeding women
• Patients with a liver disease other than non-alcoholic steatosis

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

Pituitary gland failure

Experimental group

Treatment:

Biological: Blood samples

Other: NMR

Other: fibroscan